Item Posts Archive - Page 10 of 1770 - Medivizor
Navigation Menu

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Read More

Evaluating the effectiveness and safety of aprocitentan for lowering blood pressure in patients with uncontrolled hypertension.

Evaluating the effectiveness and safety of aprocitentan for lowering blood pressure in patients with uncontrolled hypertension.

Posted by on Jul 2, 2023 in Hypertension | 0 comments

In a nutshell This study evaluated the effectiveness and safety of aprocitentan (ACT-132577) for lowering blood pressure (BP) in patients with resistant or uncontrolled hypertension (high BP). The data showed that aprocitentan was effective in lowering the BP after 4 weeks with a sustained effect after 40 weeks compared to a placebo with...

Read More

Evaluating the effectiveness and safety of indobufen plus clopidogrel versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention with drug-eluting stent.

Evaluating the effectiveness and safety of indobufen plus clopidogrel versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention with drug-eluting stent.

Posted by on Jul 2, 2023 in Coronary artery disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of indobufen (Ibustrin) plus clopidogrel (Plavix) versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES). The data showed that indobufen plus clopidogrel significantly reduced the risk of...

Read More

Evaluating the effectiveness and safety of mirabegron and solifenacin combination in patients with double-J stent related overactive bladder symptoms.

Evaluating the effectiveness and safety of mirabegron and solifenacin combination in patients with double-J stent related overactive bladder symptoms.

Posted by on Jul 2, 2023 in Overactive bladder | 0 comments

In a nutshell This study evaluated the effectiveness and safety of mirabegron (Myrbetriq) and solifenacin (Vesicare) combination in patients with double-J stent-related overactive bladder (OAB) symptoms. The study found that mirabegron and solifenacin combination significantly improved urinary symptoms, OAB symptoms, and the quality of life with...

Read More

Can new glucose-lowering medications influence stroke risk in patients with type 2 diabetes?

Can new glucose-lowering medications influence stroke risk in patients with type 2 diabetes?

Posted by on Jun 11, 2023 in Diabetes mellitus | 0 comments

In a nutshell This review assessed the effects of new glucose-lowering drugs on stroke risk in patients with type 2 diabetes (T2D). The study showed that glucagon-like peptide-1 receptor (GLP-1) agonists are potentially beneficial for stroke risk in patients with T2D. Some background Patients with diabetes are at a higher risk of developing...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor